Tenax Therapeutics (TENX) Cash from Operations: 2010-2017
Historic Cash from Operations for Tenax Therapeutics (TENX) over the last 7 years, with Dec 2017 value amounting to -$1.3 million.
- Tenax Therapeutics' Cash from Operations rose 58.71% to -$1.3 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$12.1 million, marking a year-over-year increase of 23.51%. This contributed to the annual value of -$14.8 million for FY2024, which is 150.86% down from last year.
- Tenax Therapeutics' Cash from Operations amounted to -$1.3 million in Q4 2017, which was down 4.58% from -$1.2 million recorded in Q3 2017.
- In the past 5 years, Tenax Therapeutics' Cash from Operations ranged from a high of -$1.2 million in Q3 2017 and a low of -$63.5 million during Q1 2014.
- For the 3-year period, Tenax Therapeutics' Cash from Operations averaged around -$3.3 million, with its median value being -$3.3 million (2016).
- In the last 5 years, Tenax Therapeutics' Cash from Operations tumbled by 3,927.13% in 2013 and then surged by 95.21% in 2014.
- Tenax Therapeutics' Cash from Operations (Quarterly) stood at -$60.8 million in 2013, then surged by 95.21% to -$2.9 million in 2014, then tumbled by 93.86% to -$3.8 million in 2015, then reached -$3.1 million in 2016, then surged by 58.71% to -$1.3 million in 2017.
- Its Cash from Operations was -$1.3 million in Q4 2017, compared to -$1.2 million in Q3 2017 and -$5.6 million in Q2 2017.